CSS LLC’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

CSS LLC’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,400	Closed	-$755K	–	1014
2023 Q2	$755K	Hold	7,400	–	–	0.05%	296
2023 Q1	$673K	Sell	7,400 -6,500	-47%	-$381K	0.04%	265
2022 Q4	$528K	Buy	+13,900	New	+$478K	0.03%	370
2022 Q2	–	Sell	-17,500	Closed	-$574K	–	1298
2022 Q1	$574K	Buy	+17,500	New	+$519K	0.02%	586
2021 Q4	–	Sell	-20,000	Closed	-$2.01M	–	1381
2021 Q3	$2.01M	Buy	+20,000	New	+$2.34M	0.09%	246

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

CSS LLC's RETA Position: Q1 2023 in Review

CSS LLC sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023, closing a stake of 15,693 shares — an estimated $921K sold.

CSS LLC first reported a position in RETA in Q4 2022 and held it in 1 quarter. The position peaked at $596K in Q4 2022. 205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

CSS LLC reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
CSS LLC sold 15,693 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2023, an estimated $921K.
CSS LLC first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2022 and held it in 1 quarter.
CSS LLC's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $596K in Q4 2022.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on CSS LLC's 13F filing for Q1 2023, filed 15 May 2023.